Kim Moran, Head of U.S. Rare Diseases at UCB, discusses the latest UCB data presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting that builds the body of evidence around the complexities of Myasthenia Gravis. Patients living with myasthenia gravis continue to experience high disease and treatment burden resulting in significant impact on their daily lives.
Kim Moran is Head of U.S. Rare Diseases, where she oversees the rare disease commercial organization in the U.S., preparing for future launches and building the strategy for our entry into multiple rare diseases. Kim’s career began in rare, working in myasthenia gravis, and she believes through our deep understanding of patients and their needs, we have a responsibility to be bold and take risks to deliver for them. Over her nearly 15 years at UCB, she’s seen the organization grow and evolve, giving us the opportunity to gain closer proximity to patients, understand their unmet needs, and deliver unique solutions, including through digital pathways.
Kim has served as a catalyst for change within UCB. She was part of the team who advocated for a Diversity, Equity, and Inclusion Council and a full-time U.S. Diversity Lead. She also led the U.S. organization in digital business transformation, UCB’s effort to amplify scientific innovation through digital, data, and technology in order to make a bigger impact on stakeholders and for patients. She is a member of the U.S. Leadership Team, and is passionate about leadership, employee engagement, and innovative thinking.
Most recently, Kim was Head of Insights to Impact at UCB, a role she originated leading a team across finance, strategy, and operations to leverage insights and align our resources to have the greatest impact for patients, learning from patient insights. Drawing on her training as a neuroscientist and ten years of pharma industry business experience, she is committed to ensuring UCB delivers maximum value to the patients we serve.
Kim previously served as Head of Neurology Strategy in the U.S. and Head, Epilepsy Portfolio Strategy & Evolution within the Seizure Freedom Patient Value Mission. She collaborated across the business unit to uncover patient and caregiver insights and translate them into product and program innovations that increase value to those suffering from seizure disorders and solidify UCB’s leadership position in epilepsy.
She also served as Mission Lead for brivaracetam (BRV) lifecycle and medical affairs, where she was responsible for developing both the medical affairs launch plan and the BRV lifecycle management plan. Before that she was Mission Lead for Neupro Restless Legs Syndrome (RLS) lifecycle management and pioneered an innovative platform that used increased awareness of comorbidities in RLS to drive changes in the prevailing treatment paradigms.